Kodiak Sciences Inc. Kodiak Sciences Inc.

Kodiak Sciences Inc.

KOD

Classificação em ações #3149
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Preço da ação
$91.35
Última sincronização: 2026-10-19
Valor de mercado
$5.74B
Variação (1 dia)
6.53%
Variação (1 ano)
416.10%
País
US
Negociar Kodiak Sciences Inc. (KOD)

Categoria

Healthcare
Rácio P/S de Kodiak Sciences Inc. (KOD)
Rácio P/S em October 2026 TTM: 0.00
De acordo com os relatórios financeiros mais recentes e o preço das ações da Kodiak Sciences Inc., o rácio P/S atual (TTM) é 0.00. No final de 2023, o rácio P/S era 0.00.
Histórico do rácio P/S da Kodiak Sciences Inc. de 2016 a 2026
Rácio P/S no final de cada ano
Ano Rácio P/S Alterar
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
Rácio P/S de empresas semelhantes ou concorrentes
Empresa Rácio P/S Diferença do rácio P/S País
10.02 -
US
40.55 -
US
3.96 -
AU
- -
CH
10.15 -
NL